1,074 research outputs found
Recommended from our members
Baroclinic adjustment and dissipative control of storm tracks
The steady-state response of a mid-latitude storm track to large-scale extratropical thermal forcing and eddy friction is investigated in a dry general circulation model with a zonally symmetric forcing. A two-way equilibration is found between the relative responses of the mean baroclinicity and baroclinic eddy intensity, whereby mean baroclinicity responds more strongly to eddy friction whereas eddy intensity responds more strongly to the thermal forcing of baroclinicity. These seemingly counter-intuitive responses are reconciled using the steady state of a predator-prey relationship between baroclinicity and eddy intensity. This relationship provides additional support for the well studied mechanism of baroclinic adjustment in the Earth’s atmosphere, as well as providing a new mechanism whereby eddy dissipation controls the large-scale thermal structure of a baroclinically unstable atmosphere. It is argued that these two mechanisms of baroclinic adjustment and dissipative control should be used in tandem when considering storm track equilibration
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
BACKGROUND:
Neurofilament light (NFL) has been increasingly recognized for prognostic and therapeutic decisions.
OBJECTIVE:
To validate the utility of cerebrospinal fluid NFL (cNFL) as a biomarker in clinical practice of relapsing-remitting multiple sclerosis (RRMS).
METHODS:
RRMS patients (n = 757) who had cNFL analyzed as part of the diagnostic work-up in a single academic multiple sclerosis (MS) center, 2001–2018, were retrospectively identified. cNFL concentrations were determined with two different immunoassays and the ratio of means between them was used for normalization.
RESULTS:
RRMS with relapse had 4.4 times higher median cNFL concentration (1134 [interquartile range (IQR) 499–2744] ng/L) than those without relapse (264 [125–537] ng/L, p < 0.001) and patients with gadolinium-enhancing lesions had 3.3 times higher median NFL (1414 [606.8–3210] ng/L) than those without (426 [IQR 221–851] ng/L, p < 0.001). The sensitivity and specificity of cNFL to detect disease activity was 75% and 98.5%, respectively. High cNFL at MS onset predicted progression to Expanded Disability Status Scale (EDSS) ⩾ 3 (p < 0.001, hazard ratios (HR) = 1.89, 95% CI = 1.44–2.65) and conversion to secondary progressive MS (SPMS, p = 0.001, HR = 2.5, 95% CI = 1.4–4.2).
CONCLUSIONS:
cNFL is a robust and reliable biomarker of disease activity, treatment response, and prediction of disability and conversion from RRMS to SPMS. Our data suggest that cNFL should be included in the assessment of patients at MS-onset
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: a real-world investigation
Kappa free light chain (KFLC)-index, a measure for intrathecal production of free kappa chains, has been increasingly recognized for its diagnostic potential in multiple sclerosis (MS) as a quantitative alternative to IgG oligoclonal-bands (OCBs). Our objective was to investigate the sensitivity, specificity, and overall diagnostic accuracy of KFLC-index in MS. KFLC-index was prospectively determined as part of the diagnostic workup in patients with suspected MS (n=327) between May 2013 and February 2020. Patients with clinically isolated syndrome (CIS), radiologically isolated syndrome (RIS), and MS had markedly higher KFLC-index (44.6, IQR 16-128) compared with subjects with other neuro-inflammatory disorders (ONID) and symptomatic controls (SC) (2.19, IQR 1.68-2.98, pIF and better than for IgG-index. We show that KFLC-index was influenced neither by DMT, nor by demographic factors or other inflammatory or degenerative processes in MS as determined by biomarkers in CSF
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
Cerebrospinal fluid (CSF) biomarkers can reflect different aspects of the pathophysiology of relapsing-remitting multiple sclerosis (RRMS). Understanding the impact of different disease modifying therapies on the CSF biomarker profile may increase their implementation in clinical practice and their appropriateness for monitoring treatment efficacy. This study investigated the influence of first-line (interferon beta) and second-line (natalizumab) therapies on seven CSF biomarkers in RRMS and their correlation with clinical and radiological outcomes. We included 59 RRMS patients and 39 healthy controls. The concentrations of C-X-C motif chemokine 13 (CXCL13), C-C motif chemokine ligand 2 (CCL2), chitinase-3-like protein 1 (CHI3L1), glial fibrillary acidic protein, neurofilament light protein (NFL), and neurogranin were determined by ELISA, and chitotriosidase (CHIT1) was analyzed by spectrofluorometry. RRMS patients had higher levels of NFL, CXCL13, CHI3L1, and CHIT1 than controls (p < 0.001). Subgroup analysis revealed higher NFL, CXCL13 and CHIT1 levels in patients treated with first-line therapy compared to second-line therapy (p = 0.008, p = 0.001 and p = 0.026, respectively). NFL and CHIT1 levels correlated with relapse status, and NFL and CXCL13 levels correlated with the formation of new magnetic resonance imaging lesions. Furthermore, we found an association between inflammatory and degenerative biomarkers. The results indicate that CSF levels of NFL, CXCL13, CHI3L1, and CHIT1 correlate with the clinical and/or radiological disease activity, providing additional dimensions in the assessment of treatment efficacy
Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
Neurodegeneration in multiple sclerosis (MS) correlates with disease progression and reparative processes may be triggered. Growth-associated protein 43 (GAP-43) exhibits induced expression during axonal growth and reduced expression during MS progression. We aimed to evaluate if GAP-43 can serve as a biomarker of regeneration in relapsing-remitting MS (RRMS) and whether disease-modifying therapies (DMTs) influence GAP-43 concentration in cerebrospinal fluid (CSF). GAP-43 was measured using an enzyme-linked immunosorbent assay in 105 MS patients (73 RRMS, 12 primary progressive MS, 20 secondary progressive MS) and 23 healthy controls (HCs). In 35 of the patients, lumbar puncture, clinical assessment, and magnetic resonance imaging was performed before initiation of therapeutic intervention, and at follow-up. CSF GAP-43 concentration was significantly lower in progressive MS compared with HCs (p = 0.004) and RRMS (p = < 0.001) and correlated negatively with disability (p = 0.026). However, DMTs did not alter CSF GAP-43. Interestingly, in RRMS CSF GAP-43 levels were higher in patients with signs of active inflammatory disease than in patients in remission (p = 0.042). According to CSF GAP-43 concentrations, regeneration seems reduced in progressive MS, increased during disease activity in RRMS but is unaffected by treatment of highly active DMTs
On reminder effects, drop-outs and dominance: evidence from an online experiment on charitable giving
We present the results of an experiment that (a) shows the usefulness of screening out drop-outs and (b) tests whether different methods of payment and reminder intervals affect charitable giving. Following a lab session, participants could make online donations to charity for a total duration of three months. Our procedure justifying the exclusion of drop-outs consists in requiring participants to collect payments in person flexibly and as known in advance and as highlighted to them later. Our interpretation is that participants who failed to collect their positive payments under these circumstances are likely not to satisfy dominance. If we restrict the sample to subjects who did not drop out, but not otherwise, reminders significantly increase the overall amount of charitable giving. We also find that weekly reminders are no more effective than monthly reminders in increasing charitable giving, and that, in our three months duration experiment, standing orders do not increase giving relative to one-off donations
High Interferon-gamma Uniquely in V delta 1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
We have identified a population of T lymphocytes in peripheral blood, Vδ1 TCRγδ T lymphocytes,
which unexpectedly was uniquely expressing high production of interferon-γ
in newly diagnosed, untreated multiple sclerosis (MS) patients. IFN-γ production in this
population distinctly correlated to parameters of clinical disease activity, inflammation,
and neuronal damage. These Vδ1 T lymphocytes belong to a population of innate T lymphocytes
that recognize antigen in the context of CD1d/CD1c and which include reactivity
to the myelin glycosphingolipid sulfatide. Importantly, patients treated with natalizumab,
blocking leukocyte transmigration to central nervous system, had completely normalized
levels of interferon-γ-producing Vδ1 T lymphocytes. A biomarker and early sign of demyelinating
disease in MS is much warranted and would help identify immunopathogenesis
and prognosis of disease as well as monitor success with adequate treatment. The
present study identifies the Vδ1 T lymphocytes as an early marker of MS and a possible
link to understanding the disease etiology
Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes
Conjugates of a dicarba analogue of octreotide, a potent somatostatin agonist whose receptors are overexpressed on tumor cells, with [PtCl 2(dap)] (dap = 1-(carboxylic acid)-1,2-diaminoethane) (3), [(η 6-bip)Os(4-CO 2-pico)Cl] (bip = biphenyl, pico = picolinate) (4), [(η 6-p-cym)RuCl(dap)] + (p-cym = p-cymene) (5), and [(η 6-p-cym)RuCl(imidazole-CO 2H)(PPh 3)] + (6), were synthesized by using a solid-phase approach. Conjugates 3-5 readily underwent hydrolysis and DNA binding, whereas conjugate 6 was inert to ligand substitution. NMR spectroscopy and molecular dynamics calculations showed that conjugate formation does not perturb the overall peptide structure. Only 6 exhibited antiproliferative activity in human tumor cells (IC 50 = 63 ± 2 μ in MCF-7 cells and IC 50 = 26 ± 3 μ in DU-145 cells) with active participation of somatostatin receptors in cellular uptake. Similar cytotoxic activity was found in a normal cell line (IC 50 = 45 ± 2.6 μ in CHO cells), which can be attributed to a similar level of expression of somatostatin subtype-2 receptor. These studies provide new insights into the effect of receptor-binding peptide conjugation on the activity of metal-based anticancer drugs, and demonstrate the potential of such hybrid compounds to target tumor cells specifically. © 2012 American Chemical Society
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone
BACKGROUND: Microglia-mediated proteolysis of the triggering receptor expressed on myeloid cells-2 (TREM-2) produces soluble TREM-2 (sTREM-2) that can be measured in cerebrospinal fluid (CSF) samples. Loss-of-function mutations in TREM2 or in the gene encoding its adaptor protein cause the rare Nasu–Hakola disease (NHD). Multiple sclerosis (MS) is an autoimmune disease that in common with NHD is characterized by demyelination and microglial activation. OBJECTIVE: To investigate the potential utility of sTREM-2 as a biomarker for MS and to follow treatment effects. METHODS: sTREM-2 was analyzed in CSF samples from subjects with MS (N = 59); relapsing-remitting MS (RRMS) (N = 36), secondary progressive MS (SPMS) (N = 20) and primary progressive MS (PPMS) (N = 3), and controls (N = 27). CSF levels of sTREM-2 were also assessed before and after treatment of patients with natalizumab or mitoxantrone. RESULTS: CSF levels of sTREM-2 were significantly increased in patients with RRMS, SPMS, and PPMS compared with controls. After natalizumab treatment, the levels of sTREM-2 were normalized to control levels. The levels of sTREM-2 were also reduced after mitoxantrone treatment. CONCLUSION: Increased CSF levels of sTREM-2, a new marker of microglial activation, in MS and normalization upon treatment with either natalizumab or mitoxantrone support a role for microglial activation in active MS
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
BACKGROUND:
The disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) vary
in their mode of action and when therapies are changed, the consequences on inflammatory
and degenerative processes are largely unknown.
OBJECTIVE:
We investigated the effect of switching from other DMTs to fingolimod on cerebrospinal fluid
(CSF) biomarkers.
METHODS:
43 RRMS patients were followed up after 4-12 months of fingolimod treatment.
Concentrations of C-X-C motif chemokine 13 (CXCL13), chemokine (C-C motif) ligand 2 (CCL2),
chitinase-3-like protein 1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light
protein (NFL), and neurogranin (NGRN) were analyzed by enzyme-linked immunosorbent
assay (ELISA), while chitotriosidase (CHIT1) was analyzed by spectrofluorometry.
RESULTS:
The levels of NFL, CXCL13, and CHI3L1 decreased ( p < 0.05) after fingolimod treatment.
Subgroup analysis revealed a reduction in NFL ( p < 0.001), CXCL13 ( p = 0.001), CHI3L1 (
p < 0.001), and CHIT1 ( p = 0.002) in patients previously treated with first-line therapies. In
contrast, the levels of all analyzed biomarkers were essentially unchanged in patients
switching from natalizumab.
CONCLUSION:
We found reduced inflammatory activity (CXCL13, CHI3L1, and CHIT1) and reduced axonal
damage (NFL) in patients switching from first-line DMTs to fingolimod. Biomarker levels in
patients switching from natalizumab indicate similar effects on inflammatory and
degenerative processes. The CSF biomarkers provide an additional measure of treatment
efficacy
- …